Disease Progression Analytics
Origent’s core expertise is the development of disease progression models that provide projections at the patient-level. Our models and software tools are used to arm decision makers with the insight they need for trial design, participant selection, and trial continuation or termination.
Origent works on the disease states that our clients are targeting in order to speed up their research and development efforts. Origent is current targeting the following diseases:
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Multiple Sclerosis
- Parkinson’s Disease
- Rheumatoid Arthritis
- Macular Degeneration
- Breast Cancer
Drug Rescue & Repurposing
Origent works with pharmaceutical companies, biotech firms, and CROs to analyze ongoing or past trial results in order to identify patient sub-groups for which efficacy can be proven. By employing our disease progression models, Origent can pinpoint patient cohorts which showed efficacy in specific disease areas. Clients utilize this data to re-start or re-orient trials and seek regulatory approval for specific patient groups.
Biomarker Testing and Molecule Discovery
Origent provides academic partners and clients with insights from past trial results to assist in the drug discovery process. By testing biomarkers against trial results, Origent can help shorten the development process and better predict the effectiveness of candidate compounds.
Please Contact Us to learn more about our services and how Origent can help your drug development process or patient services.